Research menu
Jump to menu

Publications:  Dr Louisa Chard

Lu S, Zhang Z, Du P, Chard LS, Yan W, Khouri ME, Wang Z, Zhang Z et al.(2020). A virus-infected, reprogrammed somatic cell–derived tumor cell (VIREST) vaccination regime can prevent initiation and progression of pancreatic cancer. Clinical Cancer Research vol. 26, (2) 465-476.
Miao J, Chard LS, Wang Z, Wang Y(2019). Syrian Hamster as an Animal Model for the Study on Infectious Diseases. Frontiers in Immunology vol. 10,
Wang P, Li X, Wang J, Gao D, Li Y, Li H, Chu Y, Zhang Z et al.(2018). Erratum: Author Correction: Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent (Nature communications (2017) 8 1 (1395)). Nature communications vol. 9, (1)
Wang P, Li X, Wang J, Gao D, Li Y, Li H, Chu Y, Zhang Z et al.(2017). Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent. Nat Commun vol. 8, (1) 1395-1395.
Yuan M, Wang P, Chard LS, Lemoine NR, Wang Y(2016). A simple and efficient approach to construct mutant vaccinia virus vectors. Journal of Visualized Experiments vol. 2016, (116)
Ahmed J, Yuan M, Li Y, Chu Y, Zhang Z, Gao D, Chard LS, Alusi G et al. (2015). 420. A Promising Neo-Adjuvant Immuno-Therapeutic Agent for Preventing Cancer Recurrence and Metastasis After Surgery. Molecular Therapy. vol. 23,
Yuan M, Gao X, Chard LS, Ali Z, Ahmed J, Li Y, Liu P, Lemoine NR et al.(2015). A marker-free system for highly efficient construction of vaccinia virus vectors using CRISPR Cas9. Molecular Therapy - Methods and Clinical Development vol. 2,
Chard LS, Maniati E, Wang P, Zhang Z, Gao D, Wang J, Cao F, Ahmed J et al.(2015). A vaccinia virus armed with interleukin-10 Is a promising therapeutic agent for treatment of murine pancreatic cancer. Clinical Cancer Research vol. 21, (2) 405-416.
Yuan M, Zhang W, Wang J, Al Yaghchi C, Ahmed J, Chard L, Lemoine NR, Wang Y(2015). Efficiently editing the vaccinia virus genome by using the CRISPR-Cas9 system. Journal of Virology vol. 89, (9) 5176-5179.
Chard LS, Lemoine NR, Wang Y(2015). New role of Interleukin-10 in enhancing the antitumor efficacy of oncolytic vaccinia virus for treatment of pancreatic cancer. OncoImmunology vol. 4, (9) 1-3.
Ahmed J, Yuan M, Li Y, Chu Y, Shi H, Chard L, Alusi G, Lemoine N et al. (2014). A Novel Tumour Selective Oncolytic Vaccinia Virus Lacking the N1L Gene Enhances the Anti-Tumour Immune Response When Used as an Anticancer Therapeutic. MOLECULAR THERAPY. vol. 22, S248-S249.
Chard LS, Maniati E, Wang P, Hughes J, Wang J, Denes B, Fodor I, Hagemann T et al. (2013). A Vaccinia Virus Armed with Interleukin-10 That Dampens Host Immunity to the Vctor but Not to Tumor Is a Promising Therapeutic Agent for Pancreatic Cancer. MOLECULAR THERAPY. vol. 21, S196-S196.
Hiley CT, Chard LS, Gangeswaran R, Tysome JR, Briat A, Lemoine NR, Wang Y(2013). Vascular endothelial growth factor A promotes vaccinia virus entry into host cells via activation of the Akt pathway. J Virol vol. 87, (5) 2781-2790.
Tysome JR, Li X, Wang S, Wang P, Gao D, Du P, Chen D, Gangeswaran R et al.(2012). A novel therapeutic regimen to eradicate established solid tumors with an effective induction of tumor-specific immunity. Clin Cancer Res vol. 18, (24) 6679-6689.
Wang P, Jiang G, Chard L, Wang J, Gao D, Cao H, Lemoine NR, Wang Y (2012). A Rationally Designed Oncolytic Adenovirus, Ad-TD-IL-12, Cures Pancreatic Cancer in the Immunocompetent Syrian Hamster. MOLECULAR THERAPY. vol. 20, S131-S131.
Hiley CT, Chard L, Lemoine N, Wang Y(2011). A novel replication-selective vaccinia virus vector to express diagnostic or therapeutic genes in hypoxic environments. HUMAN GENE THERAPY vol. 22, (10) A99-A100.
Chard LS, Bailey DS, Dash P, Banyard AC, Barrett T(2008). Full genome sequences of two virulent strains of peste-des-petits ruminants virus, the Côte d'Ivoire 1989 and Nigeria 1976 strains. Virus Res vol. 136, (1-2) 192-197.
Bailey D, Chard LS, Dash P, Barrett T, Banyard AC(2007). Reverse genetics for peste-des-petits-ruminants virus (PPRV): promoter and protein specificities. Virus Res vol. 126, (1-2) 250-255.
Bordeleau M-E, Mori A, Oberer M, Lindqvist L, Chard LS, Higa T, Belsham GJ, Wagner G et al.(2006). Functional characterization of IRESes by an inhibitor of the RNA helicase eIF4A. Nat Chem Biol vol. 2, (4) 213-220.
Chard LS, Bordeleau M-E, Pelletier J, Tanaka J, Belsham GJ(2006). Hepatitis C virus-related internal ribosome entry sites are found in multiple genera of the family Picornaviridae. J Gen Virol vol. 87, (Pt 4) 927-936.
Chard LS, Kaku Y, Jones B, Nayak A, Belsham GJ(2006). Functional analyses of RNA structures shared between the internal ribosome entry sites of hepatitis C virus and the picornavirus porcine teschovirus 1 Talfan. J Virol vol. 80, (3) 1271-1279.
Pisarev AV, Chard LS, Kaku Y, Johns HL, Shatsky IN, Belsham GJ(2004). Functional and structural similarities between the internal ribosome entry sites of hepatitis C virus and porcine teschovirus, a picornavirus. J Virol vol. 78, (9) 4487-4497.
Kaku Y, Chard LS, Inoue T, Belsham GJ(2002). Unique characteristics of a picornavirus internal ribosome entry site from the porcine teschovirus-1 talfan. J Virol vol. 76, (22) 11721-11728.
Return to top